Chunyan Zhao
Researcher | Docent
E-mail: chunyan.zhao@ki.se
Visiting address: Blickagången 16, 14151 Flemingsberg
Postal address: H7 Medicin, Huddinge, H7 Bionut Avdelningsgemensamt, 171 77 Stockholm
Part of:
About me
- I am an Associate Professor (“Docent” in the Swedish academic system) and
acting group leader for the ESR (Estrogen Signaling Research) group. I
received my PhD from Karolinska Institutet in 2000, under the supervision of
Professor Kari Hemminki. My PhD project studied the molecular mechanisms of
carcinogenesis mediated by chemical carcinogens or UV-radiation. In 2002, I
joined the ESR group, focusing at understanding estrogen signaling and AP-1
signaling in breast cancer using functional genomics approaches.
Research
- *Functional genomics of breast Cancer*
Patients with estrogen receptor (ER)-positive breast cancer are usually
treated with anti-hormone therapies such as tamoxifen or aromatase
inhibitors. However, many of these patients are resistant to these drugs or
develop resistance during treatment, allowing their breast cancer to return.
In addition, patients with triple-negative breast cancer (TNBC) have limited
treatment options. Our group is using functional genomics approaches towards
unravelling mechanisms of drug resistance in ER-positive breast cancer and
understanding molecular determinants of malignant cell behaviors in TNBC. The
ultimate goal is to develop novel and improved prognostic tools and therapies
for patients with invasive breast tumors.
Recent published results from the group showed the first evidence that the
AP-1 transcription factor Fra-1 is overexpressed in TNBC and has prognostic
value. This work provided novel insights into the mechanisms through which
TNBC cells acquire invasive and proliferative properties. Currently there are
three main projects in focus 1) Characterization of the role of AP-1 in
regulating TNBC invasiveness, in breast cancer progression and metastasis and
in breast cancer stem cells. 2) Identification of the ER cistrome associated
proteome in response to different ligands in breast cancer cells. With the
term “the ER cistrome associated proteome” we refer to the global
identification of proteins associated with primarily the DNA bound ER. 3)
Identification of the ER cistrome associated proteome in tamoxifen resistant
compared to tamoxifen sensitive breast cancer.
Articles
- Article: CANCER LETTERS. 2021;506:23-34
- Article: ONCOGENE. 2019;38(28):5725-5738
- Article: ONCOGENE. 2018;37(19):2586-2600
- Article: ONCOTARGET. 2016;7(44):71580-71593
- Article: CANCER RESEARCH. 2016;76(19):5634-5646
- Article: ONCOGENE. 2016;35(15):1955-1964
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2016;291(10):5068-5079
- Article: ONCOTARGET. 2015;6(41):43853-43868
- Article: ONCOTARGET. 2015;6(32):33623-33635
- Article: ONCOTARGET. 2015;6(10):7804-7814
- Article: ONCOGENE. 2014;33(34):4340-4351
- Article: CANCER RESEARCH. 2014;74(14):3983-3994
- Article: BMC CANCER. 2013;13:441
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2012;426(1):26-32
- Article: CARCINOGENESIS. 2012;33(9):1684-1691
- Article: SHOCK. 2012;37(4):355-359
- Article: GENOME BIOLOGY. 2012;13(3):R24
- Article: PLOS ONE. 2010;5(12):e15594
- Article: CURRENT OPINION IN PHARMACOLOGY. 2010;10(6):692-697
- Article: PLOS ONE. 2010;5(11):e14085
- Article: CANCER RESEARCH. 2010;70(12):5174-5183
- Article: CANCER RESEARCH. 2010;70(3):1265-1274
- Article: ENDOCRINE. 2009;36(2):224-232
- Article: BMC GENETICS. 2009;10:55
- Article: CANCER RESEARCH. 2009;69(15):6100-6106
- Article: JOURNAL OF MOLECULAR ENDOCRINOLOGY. 2009;43(1-2):65-72
- Article: CANCER RESEARCH. 2007;67(8):3955-3962
- Article: PHARMACOGENETICS AND GENOMICS. 2006;16(5):379-383
- Article: BIOCHEMISTRY. 2005;44(22):7936-7944
- Article: CARCINOGENESIS. 2004;25(11):2067-2073
- Article: ONCOGENE. 2003;22(48):7600-7606
- Article: BREAST CANCER RESEARCH AND TREATMENT. 2003;79(3):409-413
- Article: INTERNATIONAL JOURNAL OF CANCER. 2003;103(5):671-675
- Article: MUTAGENESIS. 2002;17(3):189-191
- Article: CARCINOGENESIS. 2002;23(4):605-609
- Article: INTERNATIONAL JOURNAL OF CANCER. 2002;98(3):331-334
- Article: CARCINOGENESIS. 2002;23(2):307-310
- Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2002;118(1):180-184
- Article: ENVIRONMENTAL AND MOLECULAR MUTAGENESIS. 2001;37(3):226-230
- Article: BIOMARKERS. 2000;5(3):168-181
- Article: CARCINOGENESIS. 2000;21(1):107-111
- Article: CHEMICAL RESEARCH IN TOXICOLOGY. 1999;12(10):979-984
- Article: MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS. 1999;424(1-2):117-125
- Article: BIOMARKERS. 1998;3(4-5):327-334
- Article: CARCINOGENESIS. 1997;18(11):2205-2208
- Article: BIOMARKERS. 1997;2(6):355-360
- Show more
All other publications
- Review: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2014;382(1):665-672
- Review: JOURNAL OF ENDOCRINOLOGY. 2012;212(1):3-12
- Review: JOURNAL OF BIOLOGICAL CHEMISTRY. 2010;285(51):39575-39579
- Review: JOURNAL OF ENDOCRINOLOGY. 2010;204(3):233-240
- Review: NUCLEAR RECEPTOR SIGNALING. 2008;6:e003
- Letter: INTERNATIONAL JOURNAL OF CANCER. 2001;92(6):923-925
- Published conference paper: REGULATORY TOXICOLOGY AND PHARMACOLOGY. 2000;32(3):264-275
- Thesis / dissertation: 2000
- Published conference paper: TOXICOLOGY LETTERS. 1998;102-103:591-594
Employments
- Researcher, Department of Medicine, Huddinge, Karolinska Institutet, 2024-
Degrees and Education
- Docent, Karolinska Institutet, 2011
- Doctor Of Philosophy, Department of Biosciences and Nutrition, Karolinska Institutet, 2000